We would love to hear your thoughts about our site and services, please take our survey here.
I did sell a little of the shares before results and bought back in. The dip is probably a mixture of worry over its margins and profit taking. Long term its solid, tbh when it was hitting 94 before results I did fear it was too high/priced in.
Paupac -With regards to US shares, its definitely been more profitable for me. I used to be fully UK FTSE but now 60% US shares. Investing in the FAANGs and semiconductors have been way more profitable for me
Most importantly in the trading update they said in Q4 the impact of Covid should have eased and they are actively working and improving the supply issues. Q3 was the brunt of Covid and supply issues so their forward outlook should please the market!
Agree this is best looked at medium to long term. Interesting to note money is flowing out of healthcare recently, Smith and Nephew is also not the only one with a lack of momentum following a positive report (I.e Astra). Just wait and people will rotate back in once portfolios are rebalanced. With banks and insurers reporting this week and relation trade (and surprisingly big tech) picking up a bit again healthcare and defensives are not hot right now
Hes always been against the vaccine from the start no matter how the stats from real world use is panning out, which shows its is as highly effective in preventing serious and hospital admissions.
All the stocks were hit today, some did drop more, its just dropped back to what's it should be now. Astra wasn't really dropping that much apart from the last 2 days. If you look at other FTSE stocks like Legal and General, Vodaphone, etc they had their drops already over the last 2 weeks. Astra is resilient but at the end of the day it cant escape a small correction. It should never have reached 88 just before the financial quarter update in the first place. Also all health care stocks dropped today, GSK, Smith and Nephew, Takeda, you name it . The defensives held out better, Coca Cola is even up!
Yep 3.72% is a bit of a drop, but not unheard of. End of the day, the £83 ish share price is fair. I expected it around here and not the £88 we saw 3 weeks ago. Don't think we are seeing the beginning of a correction yet, the FTSE isn't even overvalued to be corrected unlike the S&P. If it drops below 80 it becomes a bargain again, though I think after the earnings report if its good it might make a push upwards again.
Wouldn't call 1% a big drop considering how much the stock has risen over the last 3 months. Its trading in range, tbh better than where I thought it would be, so not suprised for a slight drop. Can't really compare to gsk, both companies at different crossroads.
There is still in 2 other clinical trials for slightly different use for it but it's success is irrelevant for AZN bigger picture. Did it really boost the share price? It will hardly dent the share price, AZN movement upwards the last few months due to its oncology profile and increasing drug approvals like today. Like the vaccine, both of these therapies won't affect the share price anymore.
To be honest nothing is bringing it down. It's a healthy drop considering it's been going up non stop the last week or so. The competition news won't affect it and the takeover will go through. 80ish is a fair price for Astra at the moment so won't be surprised if it stays here for a bit until next financial report or Q3 when the Alexion deal concludes.
Astra is probably perfect blend of growth, dividend and defensive for this climate. I think health care is a good sector to rotate to now. Also have holdings in Smith and Nephew and Takeda. Sorta regret I halved my National Grid holdings a while ago as that's also great for defensive.
Though Apple and a few of the chip companies (AMD and Qualcomm) are at a too good bargain at the moment!
A few companies are presenting data at ASCO. Maybe because of that but generally AZN is going to go up from now on with a lot of the vaccine pressure off. Personally I would wait as I'm a long term holder and 1.5/2% is not a lot in the grand scheme of things. Mid 80s to 90s target in a year I think.
The main thing from today is that we see the vaccine and COVID itself did not negatively impact the EPS as some people feared, and it shows it is being done none profit.
Also growth in its oncology lines and in China is promising, and following full year guidance. The market seems to like the results and quelled some fears! Next hurdle is how the company will present the Alexion takeover as a positive. I think it is but not all are convinced, that will be the next step to get the share price above 80 again.
Positive news ahead of the takeover in Q3
https://www.fiercepharma.com/marketing/alexion-wins-nice-backing-for-ultomiris-pnh-as-atypical-hus-decision-awaits
Yep as fleecy correctly said its to prevent another mix up with the J&J production error. AZN will find another plant and it is political as Fauci already has laid out that they have enough of the Moderna, Pfizer and J&J vacs (all American of course). AZN will find another plant as they will still use that to produce for other North American countries (such as Mexico). Its weird how the SP gets affected by a non profit vaccine but it gives a good buy point!